Target Discovery and Mechanism Deconvolution in Drug Discovery

Session Chair - Funded(s)

• TB

  Tom Bretschneider, Dr

  Associate Director
  Boehringer Ingelheim, Baden-Wurttemberg, Germany

Session Chair(s)

• YP

  Yohann Potier, PhD

  Director, Data Platform
  Tessera Therapeutics, Massachusetts, United States

Presentations:

• 10:00 AM – 10:30 AM

  Defining The Pharmacometabodynamics of Gefitinib after Intravenous Administration to the Mouse by UHPLC/MS and UPLC-IM-MS Study
  

  Robert Plumb – Waters Corporation - Milford, MA
• 10:30 AM – 11:00 AM

  Target deconvolution using compressed cellular thermal shift assay (cCETSA) influences key project decisions
  

  Aarti Kawatkar, APS – AstraZeneca
• 11:00 AM – 11:30 AM

  Metabolomics and Lipidomics Technologies for Target Discovery and Mechanism Deconvolution.
  

  Martin Giera, PhD – Leiden University Medical Center